Clinical Trials Logo

Stage IIIA Breast Cancer AJCC v7 clinical trials

View clinical trials related to Stage IIIA Breast Cancer AJCC v7.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT02474173 Terminated - Clinical trials for Triple-Negative Breast Carcinoma

Onalespib and Paclitaxel in Treating Patients With Advanced Triple Negative Breast Cancer

Start date: January 15, 2016
Phase: Phase 1
Study type: Interventional

This phase Ib trial studies the side effects and best dose onalespib when given together with paclitaxel in treating patients with triple negative breast cancer that has spread to other places in the body and usually cannot be cured or controlled with treatment (advanced). Onalespib works by blocking proper processing of proteins that are important for cancer growth. This results in inability of these proteins to work properly. Paclitaxel kills breast cancer cells by interfering with their ability to divide. Giving onalespib together with paclitaxel may be better than giving either one alone in treating patients with breast cancer.